Showing results (141-150 of 158) with videos related to
Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.Journal of Neurology|March 25, 2009
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELMichael Hutchinson, Ludwig Kappos, Peter A Calabresi, et al.Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.Brain : a Journal of Neurology|June 5, 2014
Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergeticsOscar G Vidaurre, Jeffery D Haines, Ilana Katz Sand, et al.Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.Brain : a Journal of Neurology|July 11, 2019
Early complement genes are associated with visual system degeneration in multiple sclerosisKathryn C Fitzgerald, Kicheol Kim, Matthew D Smith, et al.Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.Pageof 16